| 摘要 |
[Objectives] To observe the clinical effect of Tiaoqi Dingxian prescription combined with western medicine on epilepsy of qi constraint and phlegm stagnation type. [Methods] A total of 60 cases of patients of epilepsy of qi constraint and phlegm stagnation type admitted to Maoming Hospital Affiliated to Guangzhou University of Chinese Medicine from June 2023 to July 2024 were selected as the research subjects. They were randomly divided into the control group and the observation group using a random number table method, with 30 cases in each group. The control group was treated with levetiracetam, while the observation group was treated with Tiaoqi Dingxian prescription on the basis of the control group. Both groups were treated for 3 months, and the clinical efficacy, frequency and duration of epilepsy onset, improvement of electroencephalogram (EEG), Quality of Life in Epilepsy Inventory (QOLIE-31) scores, traditional Chinese medicine (TCM) syndrome scores, and incidence of adverse reactions were evaluated in both groups. [Results] The total effective rate in the observation group was 93.33% (28/30), compared to 73.33% (22/30) in the control group, with a statistically significant difference (P<0.05). Following treatment, the frequency and duration of epilepsy onset in both groups were decreased when compared to the pre-treatment period (P<0.05), and the frequency and duration of epilepsy onset in the observation group were lower than those in the control group (P<0.05). Following treatment, the EEG grading of both groups was improved when compared with that before treatment (P<0.05), and the EEG grading in the observation group was better than that in the control group (P<0.05). Following treatment, the QOLIE-31 scores in both groups, including epilepsy-related concerns, overall health, emotional health, energy, cognitive function, drug effects, and social function, were increased when compared to the scores recorded prior to treatment (P<0.05), and all scores in the observation group were higher than those in the control group (P<0.05). Following treatment, the TCM syndrome scores in both groups were decreased when compared to those prior to treatment (P<0.05), and the scores in the observation group were lower than those in the control group (P<0.05). The incidence of adverse reactions was observed to be 6.67% (2/30) in the observation group and 13.33% (4/30) in the control group, with no significant difference between the two groups (P>0.05). [Conclusions] The combination of Tiaoqi Dingxian prescription and levetiracetam in the treatment of epilepsy of qi constraint and phlegm stagnation type can improve clinical efficacy, alleviate patient’s symptoms and quality of life, and has good safety. |
